Scientists are advancing psychedelic medicine through innovative tools and theories. Researchers have introduced the "apical hypercontextualisation" theory, explaining how psychedelics shift cortical processing toward relational context. Concurrently, scientists engineered VCU-1012, a novel quipazine analog that selectively targets the serotonin 2A receptor to promote brain plasticity and alleviate depression-like symptoms in mice while successfully avoiding off-target gut receptors that cause nausea.
HTR2A receptor mapping tools
- ▪The Htr2a reporter mouse lines incorporate a bicistronic design with either Cre or CreERT2 to facilitate genetic labeling of cells expressing the 5-hydroxytryptamine 2A receptor.
- ▪Two of the engineered Htr2a reporter mouse lines feature enhanced green fluorescent protein fusion proteins, with one containing a humanized mouse receptor and the other containing the native mouse receptor.
- ▪Researchers developed three Htr2a reporter mouse lines using CRISPR-mediated recombination at the endogenous Htr2a locus to facilitate the identification and targeting of the 5-hydroxytryptamine 2A receptor in vivo.
Apical hypercontextualisation theory
- ▪Under the apical hypercontextualisation model, basal dendrites process local, feature-specific inputs, while apical dendrites gather remote, contextual signals and expectations from distant cortical regions and the thalamus.
- ▪The "apical hypercontextualisation" framework, published in Neuroscience & Biobehavioral Reviews, proposes a bottom-up neurobiological mechanism explaining how psychedelics alter perception and cognition through layer V cortical pyramidal neurons.
- ▪Serotonin 2A receptor agonism by psychedelics skews layer V pyramidal neuron output toward the apical compartment, causing cells to fire based on relationships and context rather than raw sensory inputs.
VCU-1012 selective psychedelic development
- ▪Researchers synthesized VCU-1012, a modified version of the psychedelic compound quipazine, designed to selectively target the serotonin 2A receptor while avoiding receptors that trigger gastrointestinal side effects.
- ▪In laboratory tests, mice treated with a single dose of VCU-1012 exhibited less passive coping behavior one day after treatment, indicating antidepressant-like effects.
- ▪VCU-1012 administration reduced anxiety in mice with chemotherapy-induced mood disturbances.
Brain plasticity mechanisms
- ▪The novel compound VCU-1012 promoted structural plasticity in mice by increasing the density of dendritic spines in the frontal cortex.
- ▪To visualize structural plasticity, researchers used a herpes simplex virus to deliver a fluorescent protein into the mouse frontal cortex, making brain cells glow green under a microscope.
Receptor selectivity engineering
- ▪Computer modeling and genetic tests showed that VCU-1012 binds to the orthosteric binding pocket of the serotonin 2A receptor differently from conventional drugs, enabling precise activation of healing pathways.
- ▪The original compound quipazine has an unusual chemical structure containing three basic nitrogen atoms, whereas most psychedelics contain only one.
- ▪To engineer VCU-1012, researchers systematically deconstructed quipazine around a quinazoline core to isolate therapeutic features from those causing stomach discomfort.
Gastrointestinal side effect reduction
- ▪Unlike its parent compound quipazine, VCU-1012 did not slow digestion when tested in mice, indicating a reduction in off-target gastrointestinal side effects.
- ▪VCU-1012 demonstrated selective activation of the serotonin 2A receptor in engineered human cells while avoiding the serotonin 3A gut receptor that causes nausea.
Story comments
Loading comments…